Cartesian Therapeutics (RNAC) Non Operating Investment Income (2023 - 2024)
Cartesian Therapeutics (RNAC) reported Non Operating Investment Income of -$6.9 million for Q1 2024, up 95.39% quarter-over-quarter from -$149.6 million in Q4 2023.
Cartesian Therapeutics (RNAC) Non Operating Investment Income (2023 - 2024) Analysis & Trends
Cartesian Therapeutics (RNAC) has 2 years of Non Operating Investment Income data on file, last reported at -$6.9 million in Q1 2024.
- Non Operating Investment Income for Q1 2024 came in at -$6.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was -$6.9 million (up 95.39% YoY), and the FY2024 annual result was -$6.9 million, up 95.39% from the prior year.
- Non Operating Investment Income climbed to -$6.9 million in Q1 2024 per RNAC's latest filing, from -$149.6 million in the prior quarter.
- Over five years, Non Operating Investment Income peaked at -$6.9 million in Q1 2024 and troughed at -$149.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -6.89 Mn |
| Mar 31, 2024 | -6.89 Mn |
| Dec 31, 2023 | -149.60 Mn |
| Dec 31, 2023 | -149.60 Mn |